Literature DB >> 16329146

Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells.

Yongliang Zhao1, Mona El-Gabry, Tom K Hei.   

Abstract

Betaig-h3 as a secreted protein induced by transforming growth factor-beta has been suggested to modulate cell adhesion and tumor formation. Although we have previously shown that downregulation of Betaig-h3 gene is involved in the cellular transformation of human bronchial epithelial cells induced by radiation, its regulation in primary human lung cancers is not clearly understood. In this study, Betaig-h3 expression was studied in 130 primary human lung carcinomas by immunohistochemistry. Betaig-h3 protein was absent or reduced by more than two-fold in 45 of 130 primary lung carcinomas relative to normal lung tissues examined. Recovery of Betaig-h3 expression in H522 lung cancer cells lacking endogenous Betaig-h3 protein significantly suppressed their in vitro cellular growth and in vivo tumorigenicity. In addition, parental H522 cancer cells are resistant to the etoposide induced apoptosis compared with normal human bronchial epithelial cells. However, recovery of Betaig-h3 expression in H522 cancer cells results in significantly higher sensitivity to apoptotic induction than parental tumor cells. IGFBP3 is upregulated in Betaigh3-transfected H522 cells that may mediate the apoptotic sensitivity and antitumor function of Betaig-h3 gene. These observations demonstrate that downregulation of Betaig-h3 gene is a frequent event and related to the tumor progression in human lung cancer. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16329146     DOI: 10.1002/mc.20167

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  30 in total

1.  TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells.

Authors:  Gengyun Wen; Michael A Partridge; Bingyan Li; Mei Hong; Wupeng Liao; Simon K Cheng; Yongliang Zhao; Gloria M Calaf; Tian Liu; Jun Zhou; Zengli Zhang; Tom K Hei
Journal:  Cancer Lett       Date:  2011-05-10       Impact factor: 8.679

2.  Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.

Authors:  Gengyun Wen; Mei Hong; Bingyan Li; Wupeng Liao; Simon K Cheng; Burong Hu; Gloria M Calaf; Ping Lu; Michael A Partridge; Jian Tong; Tom K Hei
Journal:  Int J Oncol       Date:  2011-06-23       Impact factor: 5.650

3.  Release of TGFβig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression.

Authors:  Chris Holmberg; Michael Quante; Islay Steele; Jothi Dinesh Kumar; Silviya Balabanova; Cedric Duval; Matyas Czepan; Zoltan Rakonczay; Laszlo Tiszlavicz; Istvan Nemeth; Gyorgy Lazar; Zsolt Simonka; Rosalind Jenkins; Peter Hegyi; Timothy C Wang; Graham J Dockray; Andrea Varro
Journal:  Carcinogenesis       Date:  2012-05-18       Impact factor: 4.944

4.  BIGH3 modulates adhesion and migration of hematopoietic stem and progenitor cells.

Authors:  Sofieke E Klamer; Carlijn G M Kuijk; Peter L Hordijk; C Ellen van der Schoot; Marieke von Lindern; Paula B van Hennik; Carlijn Voermans
Journal:  Cell Adh Migr       Date:  2013-10-08       Impact factor: 3.405

5.  TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Authors:  Marta Irigoyen; María J Pajares; Jackeline Agorreta; Mariano Ponz-Sarvisé; Elisabeth Salvo; María D Lozano; Ruben Pío; Ignacio Gil-Bazo; Ana Rouzaut
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

6.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

7.  The insoluble TGFBIp fraction of the cornea is covalently linked via a disulfide bond to type XII collagen.

Authors:  Kasper Runager; Gordon K Klintworth; Henrik Karring; Jan J Enghild
Journal:  Biochemistry       Date:  2013-04-15       Impact factor: 3.162

8.  C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells.

Authors:  Rogelio Zamilpa; Rajesha Rupaimoole; Clyde F Phelix; Maria Somaraki-Cormier; William Haskins; Reto Asmis; Richard G LeBaron
Journal:  Matrix Biol       Date:  2009-06-06       Impact factor: 11.583

9.  TGFBI deficiency predisposes mice to spontaneous tumor development.

Authors:  Ye Zhang; Gengyun Wen; Genze Shao; Cuidong Wang; Chyuansheng Lin; Hongbo Fang; Adayabalam S Balajee; Govind Bhagat; Tom K Hei; Yongliang Zhao
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 10.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.